Patient aged 18-80 years old with refractory chronic pain conditions, including spinal cord injury pain, phantom limb pain, complex regional pain syndrome, post-herpetic neuralgia, ischemic pain, refractory neuropathic pain, and refractory nociplastic pain. Ketamine infusion Dose response effects Refractory chronic non-cancer pain
Conditions
Interventions
Dose 0.1 mg/kg/h
Duration over 4 hours in an outpatient pain clinic, with 3 repeats (2-3 weeks apart) ,Dose 0.3 mg/kg/h
Duration over 4 hours in an outpatient pain clinic, with 3 repeats (2-3 weeks ap
Experimental Drug,Experimental Drug,Experimental Drug
low-dose ketamine infusion,moderate dose ketamine infusion,High dose ketamine infusion
Sponsors
none
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 to 80 years 2. Diagnosed with refractory chronic pain, including but not limited to the following conditions: Spinal cord injury pain Phantom limb pain Complex regional pain syndrome (CRPS) Post-herpetic neuralgia Ischemic pain Refractory neuropathic pain Refractory nociplastic pain 3.Average pain intensity of 5 out of 10 or more on the Numerical Rating Scale (NRS) during the previous 7 days at the baseline assessment. 4.Failure to respond to standard treatment for at least 3 months, including one or more of the following: Pharmacologic treatment Physical therapy Interventional pain management procedures
Exclusion criteria
Exclusion criteria: 1.Presence of financial incentives or ongoing legal or compensation claims related to the pain condition. 2.Inability to complete study assessments or questionnaires. 3.Severe psychiatric comorbidities, including active suicidality or self-harm, psychosis, post-traumatic stress disorder (PTSD), or a history of substance use disorder or substance dependence (screened using PHQ-9 and GAD-7). 4.History of severe adverse reactions to ketamine. 5.Unstable cardiovascular conditions or contraindications to ketamine, such as increased intracranial or intraocular pressure, or severe hepatic or renal impairment. 6.Pregnancy, or any other medical condition that contraindicates ketamine administration. 7.Cancer-related pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score 3 months after the final ketamine infusion NRS | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness, safety 1-6 months after the final ketamine infusion NRS, PGIC, PSQI, BPI, GAD7, PHQ9, PCS, analgesic use, adverse effects | — |
Countries
Thailand
Contacts
Public ContactSireedhorn Assavanop
King Chulalongkorn Memorial Hospital, Chulalongkorn University
Outcome results
None listed